179 related articles for article (PubMed ID: 23588628)
1. [Non alcoholic fatty liver disease: a new risk factor for cardiovascular disease?].
Sdiri W; Romdhane H; Mbarek D; Ben Abdallah H; Longo S; Abdelli MN; Boujnah MR
Tunis Med; 2013 Mar; 91(3):171-4. PubMed ID: 23588628
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
[TBL] [Abstract][Full Text] [Related]
3. Update on the treatments of non-alcoholic fatty liver disease (NAFLD).
Quercioli A; Montecucco F; Mach F
Cardiovasc Hematol Disord Drug Targets; 2009 Dec; 9(4):261-70. PubMed ID: 19751186
[TBL] [Abstract][Full Text] [Related]
4. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences.
Del Ben M; Baratta F; Polimeni L; Angelico F
Intern Emerg Med; 2012 Oct; 7 Suppl 3():S291-6. PubMed ID: 23073870
[TBL] [Abstract][Full Text] [Related]
5. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis.
Pacana T; Fuchs M
Clin Liver Dis; 2012 Aug; 16(3):599-613. PubMed ID: 22824483
[TBL] [Abstract][Full Text] [Related]
6. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
7. Does non-alcoholic fatty liver disease (NAFLD) increase cardiovascular risk?
Montecucco F; Mach F
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):301-7. PubMed ID: 19075784
[TBL] [Abstract][Full Text] [Related]
8. [Pediatric non-alcoholic fatty liver disease: recent advances and challenges].
Poggiogalle E; Olivero G; Anania C; Ferraro F; Pacifico L
Minerva Pediatr; 2010 Dec; 62(6):569-84. PubMed ID: 21042270
[TBL] [Abstract][Full Text] [Related]
9. Ectopic fat, insulin resistance and non-alcoholic fatty liver disease.
Byrne CD
Proc Nutr Soc; 2013 Nov; 72(4):412-9. PubMed ID: 23668723
[TBL] [Abstract][Full Text] [Related]
10. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease.
Byrne CD; Targher G
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1155-61. PubMed ID: 24743428
[TBL] [Abstract][Full Text] [Related]
11. The central role of the non alcoholic fatty liver disease in metabolic syndrome.
Hurjui DM; Niţă O; Graur LI; Mihalache L; Popescu DS; Graur M
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):425-31. PubMed ID: 23077931
[TBL] [Abstract][Full Text] [Related]
12. Role of diet and nutritional management in non-alcoholic fatty liver disease.
Fan JG; Cao HX
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
[TBL] [Abstract][Full Text] [Related]
13. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications.
Pickhardt PJ; Hahn L; Muñoz del Rio A; Park SH; Reeder SB; Said A
AJR Am J Roentgenol; 2014 Apr; 202(4):752-8. PubMed ID: 24660702
[TBL] [Abstract][Full Text] [Related]
14. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
15. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
Yilmaz Y
Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
[TBL] [Abstract][Full Text] [Related]
16. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.
Mikolasevic I; Racki S; Zaputovic L; Lukenda V; Milic S; Orlic L
Med Hypotheses; 2014 Feb; 82(2):205-8. PubMed ID: 24365277
[TBL] [Abstract][Full Text] [Related]
17. Review article: the metabolic syndrome and non-alcoholic fatty liver disease.
Loria P; Lonardo A; Carulli L; Verrone AM; Ricchi M; Lombardini S; Rudilosso A; Ballestri S; Carulli N
Aliment Pharmacol Ther; 2005 Nov; 22 Suppl 2():31-6. PubMed ID: 16225469
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
Kim HS; Cho YK
Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
[TBL] [Abstract][Full Text] [Related]
19. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers.
Edens MA; Kuipers F; Stolk RP
Obes Rev; 2009 Jul; 10(4):412-9. PubMed ID: 19413701
[TBL] [Abstract][Full Text] [Related]
20. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome.
Yki-Järvinen H
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):901-10. PubMed ID: 24731669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
